Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma.
Hodgkin lymphoma
TK1
Thymidine kinase
chemotherapy
prognostic markers
Journal
Upsala journal of medical sciences
ISSN: 2000-1967
Titre abrégé: Ups J Med Sci
Pays: Sweden
ID NLM: 0332203
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
11
2020
revised:
26
04
2021
accepted:
27
04
2021
entrez:
2
9
2021
pubmed:
3
9
2021
medline:
14
1
2022
Statut:
epublish
Résumé
Thymidine kinase 1 (TK1) is an intracellular protein associated with DNA synthesis, expressed during the G1 phase and remained elevated through the M phase, with a potential as a biomarker for cell proliferation. In this study, we explore the possible use of TK1 in Hodgkin lymphoma (HL). Serum concentrations of TK1 (S-TK1) were measured in 46 newly diagnosed HL patients using prospectively collected biobanked serum samples. The samples were analyzed using a novel antibody-based TK1 immunosorbent assay (ELISA). The concentrations of S-TK1 were elevated in HL patients compared with healthy controls (median 0.32 μg/L vs. 0.24 μg/L, The study results suggest that S-TK1, measured using a novel antibody-based assay, has the potential to be a biomarker in HL. However, while S-TK1 levels are elevated at baseline compared with healthy controls, a limited number of patients and comparatively short follow-up time render reliable conclusions difficult.
Sections du résumé
BACKGROUND
BACKGROUND
Thymidine kinase 1 (TK1) is an intracellular protein associated with DNA synthesis, expressed during the G1 phase and remained elevated through the M phase, with a potential as a biomarker for cell proliferation. In this study, we explore the possible use of TK1 in Hodgkin lymphoma (HL).
METHODS
METHODS
Serum concentrations of TK1 (S-TK1) were measured in 46 newly diagnosed HL patients using prospectively collected biobanked serum samples. The samples were analyzed using a novel antibody-based TK1 immunosorbent assay (ELISA).
RESULTS
RESULTS
The concentrations of S-TK1 were elevated in HL patients compared with healthy controls (median 0.32 μg/L vs. 0.24 μg/L,
CONCLUSIONS
CONCLUSIONS
The study results suggest that S-TK1, measured using a novel antibody-based assay, has the potential to be a biomarker in HL. However, while S-TK1 levels are elevated at baseline compared with healthy controls, a limited number of patients and comparatively short follow-up time render reliable conclusions difficult.
Identifiants
pubmed: 34471484
doi: 10.48101/ujms.v126.6119
pii: 6119
pmc: PMC8383933
doi:
Substances chimiques
Antibodies
0
Biomarkers, Tumor
0
Thymidine Kinase
EC 2.7.1.21
thymidine kinase 1
EC 2.7.1.21
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2021 The Author(s). Published by Upsala Medical Society.
Déclaration de conflit d'intérêts
Staffan Eriksson: co-inventor of TK1 patents licensed to DiaSorin Inc and AroCell AB as well as a consultant and shareholder in AroCell AB. Daniel Molin: Honoraria from Roche, Merck, Bristol-Myers Squibb, and Takeda. All other authors declare no competing financial interests.
Références
Br J Cancer. 1993 Dec;68(6):1227-31
pubmed: 8260377
Am J Hematol. 2015 Jun;90(6):499-503
pubmed: 25720750
Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):363-9
pubmed: 20544521
Acta Oncol. 2018 Feb;57(2):187-194
pubmed: 28631533
Biotechniques. 2020 Jun;68(6):334-341
pubmed: 32336110
Scand J Haematol. 1983 Jul;31(1):49-56
pubmed: 6867608
Biomark Med. 2018 Sep;12(9):1035-1048
pubmed: 30039979
N Engl J Med. 1998 Nov 19;339(21):1506-14
pubmed: 9819449
J Nucl Med. 2013 May;54(5):683-90
pubmed: 23516309
Cancer Res. 1971 Nov;31(11):1860-1
pubmed: 5121694
Cancer Lett. 2012 Mar;316(1):6-10
pubmed: 22068047
Nucleosides Nucleotides Nucleic Acids. 2018;37(12):679-686
pubmed: 30520339
Acta Radiol Oncol. 1985 Mar-Apr;24(2):167-71
pubmed: 2988280
N Engl J Med. 1993 Sep 30;329(14):987-94
pubmed: 8141877
Am J Clin Pathol. 2010 Sep;134(3):472-7
pubmed: 20716805